This review discusses the role of nanoformulations in pharmaceutical and biomedical applications, emphasizing green design strategies. It highlights the importance of nanotechnology in improving drug delivery, bioavailability, and targeted therapy. The paper explores various nanopharmaceuticals, including nanomicelles, lipid-based nanoparticles, liposomes, dendrimers, carbon nanomaterials, and metal-based nanopharmaceuticals. These formulations offer advantages such as enhanced solubility, targeted drug delivery, controlled release, and reduced toxicity. The review also discusses the challenges and opportunities in the development of nanopharmaceuticals, including safety concerns and the need for eco-friendly synthesis methods. Examples of nanopharmaceuticals, such as Doxil, Abraxane, and Feraheme, are provided to illustrate their clinical applications. The paper emphasizes the potential of nanotechnology in improving healthcare outcomes, particularly in cancer treatment, infectious diseases, and personalized medicine. It also highlights the importance of using natural resources in the "green" design of nanopharmaceuticals and the need for further research to ensure their safety and efficacy. The review concludes with a discussion on the future directions of nanopharmaceuticals, including the development of advanced nanosystems for improved diagnostics and therapeutics.This review discusses the role of nanoformulations in pharmaceutical and biomedical applications, emphasizing green design strategies. It highlights the importance of nanotechnology in improving drug delivery, bioavailability, and targeted therapy. The paper explores various nanopharmaceuticals, including nanomicelles, lipid-based nanoparticles, liposomes, dendrimers, carbon nanomaterials, and metal-based nanopharmaceuticals. These formulations offer advantages such as enhanced solubility, targeted drug delivery, controlled release, and reduced toxicity. The review also discusses the challenges and opportunities in the development of nanopharmaceuticals, including safety concerns and the need for eco-friendly synthesis methods. Examples of nanopharmaceuticals, such as Doxil, Abraxane, and Feraheme, are provided to illustrate their clinical applications. The paper emphasizes the potential of nanotechnology in improving healthcare outcomes, particularly in cancer treatment, infectious diseases, and personalized medicine. It also highlights the importance of using natural resources in the "green" design of nanopharmaceuticals and the need for further research to ensure their safety and efficacy. The review concludes with a discussion on the future directions of nanopharmaceuticals, including the development of advanced nanosystems for improved diagnostics and therapeutics.